1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org. Accessed: 05.06.2025.
2. Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104-23 [Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: Dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-23 (in Russian)]. DOI:10.14341/DM13035
3. Регистр сахарного диабета. Режим доступа: https://sd.diaregistry.ru/content/o-proekte.html#content. Ссылка активна на 05.06.2025 [Registr sakharnogo diabeta. Available at: https://sd.diaregistry.ru/content/o-proekte.html#content. Accessed: 05.06.2025 (in Russian)].
4. Misra S, Holman N, Barron E, et al. Characteristics and care of young people with type 2 diabetes included in the national diabetes audit datasets for England. Diabet Med. 2023;40(1):e14940. DOI:10.1111/dme.14940
5. Драпкина О.М., Концевая А.В., Калинина А.М., и др. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024;23(3):3696 [Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996 (in Russian)]. DOI:10.15829/1728-8800-2024-3996
6. Анциферов М.Б., Котенко О.Н., Кобалава Ж.Д., и др. Оценка распространенности хронической болезни почек у пациентов с сахарным диабетом 2 типа, госпитализированных в многопрофильные стационары: результаты проспективного наблюдательного многоцентрового исследования (КРЕДО). Сахарный диабет. 2024;27(3):204-13 [Antsiferov MB, Kotenko ON, Kobalava ZD, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes admitted to multidisciplinary hospitals: results of a prospective observational multicenter study (CREDO). Diabetes mellitus. 2024;27(3):204-13 (in Russian)]. DOI:10.14341/DM13146
7. Анциферов М.Б., Кобалава Ж.Д., Демидова Т.Ю., и др. Оценка распространенности хронической сердечной недостаточности у пациентов с сахарным диабетом 2 типа, госпитализированных в многопрофильные стационары: результаты проспективного наблюдательного многоцентрового исследования (КРЕДО). Сахарный диабет. 2024;27(1):4-14 [Antsiferov MB, Kobalava ZhD, Demidova TY, et al. Prevalence of heart failure among hospitalized patient with T2D: results of a prospective observational multicenter study (CREDO). Diabetes Mellitus. 2024;27(1):4-14 (in Russian)].  DOI:10.14341/DM13124
8. Рымар О.Д., Щербакова Л.В., Щетинина А.О., и др. Базовые клинико-лабораторные показатели при сахарном диабете 2 типа и риск сердечно-сосудистой смерти. Российский кардиологический журнал. 2020;25(4):3822 [Rymar OD, Shcherbakova LV, Shchetinina AO, et al. Type 2 diabetes: basic clinical and laboratory parameters and risk of cardiovascular death. Russian Journal of Cardiology. 2020;25(4):3822 (in Russian)]. DOI:10.15829/1560-4071-2020-3822
9. Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic review. Cureus. 2022;14(6):e26180. DOI:10.7759/cureus.26180
10. Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 Million person-years of observation. Lancet Diabetes Endocrinol. 2023;11(10):731-42. DOI:10.1016/S2213-8587(23)00223-1
11. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. Сахарный диабет. 2023;26(2S):1-231 [Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of Specialized Diabetes Care. Ed. by II Dedov, MV Shestakova, AYu Mayorov. 11th Edition. Diabetes Mellitus. 2023;26(2S):1-231 (in Russian)]. DOI:10.14341/DM13042 
12. Моткова С.И., Савельева Л.В., Рудина Л.М., и др. Мультидисциплинарный подход к изменению образа жизни у пациентов с сахарным диабетом 2 типа в реальной клинической практике. Результаты программы «Жизнь легка». Сахарный диабет. 2019;22(2):115-26 [Motkova SI, Savelyeva LV, Rudina LM, et al. Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application “Life is easy” programme in Russia. Diabetes Mellitus. 2019;22(2):115-26 (in Russian)]. DOI:10.14341/DM1000
13. Мисникова И.В., Ковалева Ю.А., Исаков М.А., Древаль А.В. Структура сахароснижающей терапии в особых группах пациентов с сахарным диабетом 2 типа на основании данных регистра Московской области. Сахарный диабет. 2019;22(3):206-16 [Misnikova IV, Kovaleva YuA, Isakov MА, Dreval AV. The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow Region Register. Diabetes Mellitus. 2019;22(3):206-16 (in Russian)]. DOI:10.14341/DM10084
14. Друк И.В., Снарская Д.И., Горощеня О.И. Потенциальная избыточность терапии сахарного диабета 2 типа в реальной клинической практике: данные регистра Омской области. Сахарный диабет. 2021;24(2):100-10 [Druk IV, Snarskaya DI, Goroshchenya OI. Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast Register data. Diabetes mellitus. 2021;24(2):100-10 (in Russian)]. DOI:10.14341/DM12469
15. Куркин Д.В., Макарова Е.В., Крысанов И.С., и др. Характеристики закупок сахароснижающих лекарственных средств в коммерческом секторе в динамике за 2016–2020 гг. Проблемы эндокринологии. 2023;69(4):50-60 [Kurkin DV, Makarova EV, Krysanov IS, et al. Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016–2020 years dynamics. Problems of Endocrinology. 2023;69(4):50-60 (in Russian)]. DOI:10.14341/probl13200
16. Khunti K, Zaccardi F, Amod A, et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia. 2025;68(1):17-28. DOI:10.1007/s00125-024-06254-w 
17. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl. 1):S158-78. DOI:10.2337/dc24-S009. Erratum in: Diabetes Care. 2024;47(7):1238. DOI:10.2337/dc24-er07a 
18. ElSayed NA, Aleppo G, Aroda VR, et al.; on behalf of the American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S140-57. DOI:10.2337/dc23-S009 
19. Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: Early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11(11):2465-76. DOI:10.1007/s13300-020-00926-7
20. Шестакова М.В., Анциферов М.Б., Аметов А.С., и др. Какие новые возможности для клинической практики открывает исследование VERIFY и какова его ценность для пациентов с впервые выявленным СД 2 типа? Совместное заключение по итогам экспертного совета. 6 ноября 2019 г. Сахарный диабет. 2020;23(1):106-10 [Shestakova MV, Antsiferov MB, Ametov AS, et al. What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019. Diabetes mellitus. 2020;23(1):106-10 (in Russian)]. DOI:10.14341/DM12404
21. Kalra S, Das AK, Priya G, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7. DOI:10.4103/jfmpc.jfmpc_843_20 
22. Вербовой А.Ф., Вербовая Н.И., Долгих Ю.А. Фиксированные комбинации сахароснижающих препаратов в лечении пациентов с сахарным диабетом 2-го типа. Медицинский совет. 2022;16(23):199-204 [Verbovoy AF, Verbovaya NI, Dolgikh YuA. Fixed combinations of hypoglycemic drugs in the treatment of patients with type 2 diabetes. Meditsinskiy Sovet = Medical Council. 2022;16(23):199-204 (in Russian)]. DOI:10.21518/2079-701X-2022-16-23-199-204
23. Ndefo UA, Okoli O, Erowele G. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm. 2014;71(2):103-9. DOI:10.2146/ajhp130131 
24. Зырянов С.К., Бутранова О.И. Сахароснижающие средства в гериатрии. М.: ГЭОТАР-Медиа, 2024 [Zyrianov SK, Butranova OI. Sakharosnizhaiushchie sredstva v geriatrii. Moscow: GEOTAR-Media, 2024 (in Russian)].
25. Dudkowski C, Tsai M, Liu J, et al. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2017;73(3):279-88. DOI:10.1007/s00228-016-2175-1
26. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499-512. DOI:10.1016/j.clinthera.2008.03.004
27. Okondo MC, Johnson DC, Sridharan R, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13:46-53. DOI:10.1038/nchembio.2229
28. Jones L, Jones AM. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? Pharmacol Res Perspect. 2022;10(6):e01029. DOI:10.1002/prp2.1029
29. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501-14. DOI:10.1007/BF03261927
30. Kaku K, Kisanuki K, Shibata M, Oohira T. Benefit-Risk assessment of alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf. 2019;42(11):1311-27. DOI:10.1007/s40264-019-00857-8
31. Лобанова К.Г., Северина А.С., Мартынов С.А., и др. Контроль гликемии у пациентов с сахарным диабетом на программном гемодиализе. Терапевтический архив. 2019;91(10):124-34 [Lobanova KG, Severina AS, Martinov SA, et al. Glycemic control in patients with diabetes mellitus on hemodialysis. Terapevticheskii Arkhiv (Ter. Arkh). 2019;91(10):124-34 (in Russian)]. DOI:10.26442/00403660.2019.10.000352
32. Park SH, Nam JY, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore). 2016;95(32):e4543. DOI:10.1097/MD.0000000000004543 
33. Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015;6(6):840-9. DOI:10.4239/wjd.v6.i6.840
34. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: A meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord. 2013;13:9. DOI:10.1186/1472-6823-13-9
35. Marino AB, Cole SW. Alogliptin: Safety, efficacy, and clinical implications. J Pharm Pract. 2015;28(1):99-106. DOI:10.1177/0897190014522063
36. Шестакова М.В., Качко В.А. ENTIRE: исследование реальной клинической практики применения алоглиптина в терапии пациентов с сахарным диабетом 2 типа в РФ. РМЖ. 2019;8(I):3-10 [Shestakova MV, Kachko VA. ENTIRE: real clinical practice study on alogliptin application in the treatment of patients with type 2 diabetes mellitus in the Russian Federation. Russian Medical Journal. 2019;27(8-1):3-10 (in Russian)].
37. Фадеев В.В. Результаты первого ретроспективного исследования алоглиптина по сравнению с другими пероральными сахароснижающими препаратами у пациентов с сахарным диабетом 2 типа в России ARRIVAL. Эффективная фармакотерапия. 2023;19(12):6-14 [Fadeev VV. Results of the first retrospective study of alogliptin compared with other oral hypoglycemic drugs in patients with type 2 diabetes mellitus in Russia ARRIVAL. Effektivnaya Pharmacoterapiya. 2023;19(12):6-14 (in Russian)]. DOI:10.33978/2307-3586-2023-19-12-6-14
38. Cavender MA, White WB, Liu Y, et al. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clin Cardiol. 2018;41(8):1022-7. DOI:10.1002/clc.22960
39. Mancheva M, Paljoskovska Jordanova S, Bosevski M. Carotid intima media thickness is in a relation to risk factors for coronary artery disease. Angiol Sosud Khir. 2020;26(4):11-6. DOI:10.33529/ANGIO2020412
40. Lv Q, Yang Y, Lv Y, et al. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: A systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2024;15:1403606. DOI:10.3389/fendo.2024.1403606
41. Mita T, Katakami N, Yoshii H, et al. Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: An extension of the SPEAD-A study. Sci Rep. 2023;13(1):14649. DOI:10.1038/s41598-023-41036-1
42. Layman SN, Elliott WV, Neu DW, et al. Alogliptin and heart failure outcomes in patients with type 2 diabetes. J Pharm Pract. 2024;37(2):410-4. DOI:10.1177/08971900221135656
43. Enzan N, Matsushima S, Kaku H, et al. Beneficial effects of dipeptidyl peptidase-4 inhibitors on heart failure with preserved ejection fraction and diabetes. JACC Asia. 2023;3(1):93-104. DOI:10.1016/j.jacasi.2022.09.015
44. Echouffo-Tcheugui JB, Kaze AD, Fonarow GC, Dagogo-Jack S. Severe hypoglycemia and incident heart failure among adults with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(3):e955-62. DOI:10.1210/clinem/dgab794
45. Shibuki K, Shimada S, Aoyama T. Meta-analysis of 11 heterogeneous studies regarding dipeptidyl peptidase 4 inhibitor add-on therapy for type 2 diabetes mellitus patients treated with insulin. J Diabetes Res. 2020;2020:6321826. DOI:10.1155/2020/6321826
46. Шестакова М.В., Шестакова Е.А., Качко В.А. Особенности применения алоглиптина у различных групп пациентов с сахарным диабетом 2 типа: дополнительные результаты исследования ENTIRE. Проблемы эндокринологии. 2020;66(2):49-60 [Shestakova MV, Shestakova EA, Kachko VA. Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: Additional results of the ENTIRE study. Problems of Endocrinology. 2020;66(2):49-60 (in Russian)]. DOI:10.14341/probl12273
47. Kutoh E, Kuto AN, Akiyama M, et al. Alogliptin: A DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. Eur J Clin Pharmacol. 2023;79(7):947-59. DOI:10.1007/s00228-023-03506-3
48. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: A 2-year study. Diabetes Obes Metab. 2014;16(12):1239-46. DOI:10.1111/dom.12377
49. El-Sahar AE, Shiha NA, El Sayed NS, Ahmed LA. Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 signaling pathways. Int J Neuropsychopharmacol. 2021;24(2):158-69. DOI:10.1093/ijnp/pyaa078
50. El-Sayed SS, Ali SO, Ibrahim WW. Potential neuroprotective and autophagy-enhancing effects of alogliptin on lithium/pilocarpine-induced seizures in rats: Targeting the AMPK/SIRT1/Nrf2 axis. Life Sci. 2024;352:122917. DOI:10.1016/j.lfs.2024.122917
51. Safar MM, Abdelkader NF, Ramadan E, et al. Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease. Life Sci. 2021;287:120132. DOI:10.1016/j.lfs.2021.120132 
52. Dhureja M, Deshmukh R. Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents. Eur J Pharmacol. 2024;975:176635. DOI:10.1016/j.ejphar.2024.176635
53. McFarthing K, Buff S, Rafaloff G, et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2024 Update. J Parkinsons Dis. 2024;14(5):899-912. DOI:10.3233/JPD-240272
54. Ueki K, Tanizawa Y, Nakamura J, et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: A 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care. 2021;9(1):e001787. DOI:10.1136/bmjdrc-2020-001787
55. Pradhan R, Yu OHY, Platt RW, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: A UK population-based cohort study. BMJ Open Diabetes Res Care. 2023;11(6):e003550. DOI:10.1136/bmjdrc-2023-003550
56. Zhang YS, Zheng YD, Yuan Y, et al. Effects of anti-diabetic drugs on fracture risk: A systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2021;12:735824. DOI:10.3389/fendo.2021.735824
57. Петунина Н.А., Гончарова Е.В., Кузина И.А., и др. Роль пиоглитазона в борьбе с инсулинорезистентностью, атеросклерозом, сердечно-сосудистыми заболеваниями и неалкогольной жировой болезнью печени. Сахарный диабет. 2022;25(5):504-13 [Petunina NA, Goncharova EV, Kuzina IA, et al. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes Mellitus. 2022;25(5):504-13 (in Russian)]. DOI:10.14341/DM12859
58. Christensen ML, Meibohm B, Capparelli EV, et al. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol. 2005;45(10):1137-44. DOI:10.1177/0091270005279578
59. Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2019;9(1):5389. DOI:10.1038/s41598-019-41854-2
60. Ipsen EØ, Madsen KS, Chi Y, et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11(11):CD013516. DOI:10.1002/14651858.CD013516.pub2
61. White U, Fitch MD, Beyl RA, et al. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: A randomised controlled trial. Diabetologia. 2021;64(1):159-67. DOI:10.1007/s00125-020-05281-7
62. Arbas R, Dayrit SA, Dimalanta A, et al. A meta-analysis of randomized clinical trials on the effect of metformin vs. pioglitazone monotherapy on plasma adiponectin levels among patients with diabetes mellitus. Egypt J Intern Med. 2024;36:5. DOI:10.1186/s43162-023-00269-2
63. Chang ML, Tai J, Cheng JS, et al. Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study. Diabetes Obes Metab. 2024;26(7):2969-78. DOI:10.1111/dom.15622
64. Choi SS, Park J, Choi JH. Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep. 2014;47(11):599-608. DOI:10.5483/bmbrep.2014.47.11.174 
65. Остроумова О.Д., Голобородова И.В. Лекарственно-индуцированная сердечная недостаточность (часть 1: актуальность, распространенность, причины). Безопасность и риск фармакотерапии. 2020;8(1):23-35 [Ostroumova OD, Goloborodova IV. Drug-induced heart failure (Part 1: The urgency of the problem, the prevalence, the effect of certain groups of drugs on the risk of development/progression heart failure). Safety and Risk of Pharmacotherapy. 2020;8(1):23-35 (in Russian)]. DOI:10.30895/2312-7821-2020-8-1-23-35
66. Cheng D, Gao H, Li W. Long-term risk of rosiglitazone on cardiovascular events – A systematic review and meta-analysis. Endokrynol Pol. 2018;69(4):381-94. DOI:10.5603/EP.a2018.0036
67. Салухов В.B., Ковалевская Е.А. Переосмысление роли пиоглитазона в современной диабетологии с позиции его кардиоренопротективных свойств. Медицинский совет. 2022;(10):10-21 [Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet = Medical Council. 2022;(10):10-21 (in Russian)]. DOI:10.21518/2079-701X-2022-16-10-10-21 
 68. Аметов А.С., Пьяных О.П., Вовк П.С. Перспективы применения пиоглитазона в профилактике и терапии сахарного диабета 2 типа и его осложнений. Эндокринология: новости, мнения, обучение. 2022;11(2):56-63 [Ametov АS, Pyanykh OP, Vovk PS. Benefits for pioglitazone in prevention and treatment of type 2 diabetes mellitus and its complications. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Training. 2022;11(2):56-63 (in Russian)]. DOI:10.33029/2304-9529-2022-11-2-56-63
69. Nesti L, Tricò D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: A new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. DOI:10.1186/s12933-021-01294-7
70. Yen FS, Wang HC, Pan CW, et al. Pioglitazone exposure reduced the risk of all-cause mortality in insulin-treated patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2020;105(3):dgz026. DOI:10.1210/clinem/dgz026
71. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927. DOI:10.1136/bmjopen-2016-013927 
72. Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diab Rep. 2019;19(12):151. DOI:10.1007/s11892-019-1270-y 
73. Lu Y, Ma D, Xu W, et al. Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig. 2015;6(1):78-86. DOI:10.1111/jdi.12246
74. Lee M, Saver JL, Liao HW, et al. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke. 2017;48(2):388-93. DOI:10.1161/STROKEAHA.116.013977
75. de Jong M, van der Worp HB, van der Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16(1):134. DOI:10.1186/s12933-017-0617-4
76. Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. DOI:10.1210/clinem/dgz252
77. Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials. Sci Rep. 2020;10(1):15781. DOI:10.1038/s41598-020-72967-8
78. Mannucci E, Giaccari A, Gallo M, et al.; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2022;32(3):529-36. DOI:10.1016/j.numecd.2021.12.006
79. Yang J, Shi X, Wang Y, et al. Multi-target neuroprotection of thiazolidinediones on Alzheimer's disease via neuroinflammation and ferroptosis. J Alzheimers Dis. 2023;96(3):927-45. DOI:10.3233/JAD-230593
80. Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284-94. DOI:10.1002/ana.24439
81. Lu CH, Yang CY, Li CY, et al. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: A population-based longitudinal study. Diabetologia. 2018;61(3):562-73. DOI:10.1007/s00125-017-4499-5
82. Megiri N, Mostafa YM, Ahmed A, et al. Pioglitazone ameliorates hippocampal neurodegeneration, disturbances in glucose metabolism and AKT/mTOR signaling pathways in pentyelenetetrazole-kindled mice. Pharmaceuticals (Basel). 2022;15(9):1113. DOI:10.3390/ph15091113
83. Lee HM, Hahn SJ, Choi BH. The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state. Korean J Physiol Pharmacol. 2022;26(2):135-44. DOI:10.4196/kjpp.2022.26.2.135 
84. Lee HM, Yoon SH, Kim MG, et al. Effects of rosiglitazone, an antidiabetic drug, on Kv3.1 channels. Korean J Physiol Pharmacol. 2023;27(1):95-103. DOI:10.4196/kjpp.2023.27.1.95
85. Harrer DC, Lüke F, Pukrop T, et al. Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. Front Oncol. 2024;13:1289222. DOI:10.3389/fonc.2023.1289222
86. Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018;135:102-10. DOI:10.1016/j.diabres.2017.11.002
87. Espinoza SE, Wang CP, Tripathy D, et al. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr). 2016;38(5-6):485-93. DOI:10.1007/s11357-016-9946-6
88. Yen CL, Wu CY, Tsai CY, et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: A national cohort study. Aging (Albany NY). 2023;15(7):2721-33. DOI:10.18632/aging.204643
89. Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A meta-analysis. Front Endocrinol (Lausanne). 2021;12:615409. DOI:10.3389/fendo.2021.615409. Corrigendum: Front Endocrinol (Lausanne). 2021;13:840299. DOI:10.3389/fendo.2022.840299
90. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210-9. DOI:10.1177/0091270009338938
91. Scheen AJ. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(6):1005-20. DOI:10.1517/17425255.2015.1041499
92. Hwang I, Kim Y, Yoo H, et al. Pharmacokinetic/pharmacodynamic interaction between evogliptin and pioglitazone in healthy male subjects. Drug Des Devel Ther. 2020;14:4493-502. DOI:10.2147/DDDT.S275336
93. Anson M, Henney AE, Zhao SS, et al. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. Diabetes Obes Metab. 2024;26(7):2606-23. DOI:10.1111/dom.15576
94. Tomlinson B, Chan P, Lam CWK. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2022;23(1):29-42. DOI:10.1080/14656566.2021.1985465
95. Демидова Т.Ю., Ушанова Ф.О., Жаркова П.О. Гликемические и негликемические преимущества применения фиксированной комбинации алоглиптина и пиоглитазона в управлении сахарным диабетом. FOCUS Эндокринология. 2021;4:39-48 [Demidova ТYu, Ushanova FО, Zharkova PО. Glycemic and non-glycemic benefits of using the fixed dose combination of alogliptin and pioglitazone in management of diabetes mellitus. FOCUS Endocrinology. 2021;4:39-48 (in Russian)]. DOI:10.47407/ef2021.2.4.0048
96. Pratley RE, Reusch JE, Fleck PR, et al.; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361-71. DOI:10.1185/03007990903156111
97. Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028-35. DOI:10.1111/j.1463-1326.2011.01460.x
98. Kaku K, Katou M, Igeta M, et al. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab. 2015;17(12):1198-201. DOI:10.1111/dom.12555
99. Kim HJ, Jeong IK, Hur KY, et al. Comparison of efficacy of glimepiride, alogliptin, and alogliptin-pioglitazone as the initial periods of therapy in patients with poorly controlled type 2 diabetes mellitus: An open-label, multicenter, randomized, controlled study. Diabetes Metab J. 2022;46(5):689-700. DOI:10.4093/dmj.2021.0183
100. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565-74. DOI:10.1530/EJE-13-0639
101. Park JY, Lee J, Choi YH, et al. Efficacy and safety of alogliptin-pioglitazone combination for type 2 diabetes mellitus poorly controlled with metformin: A multicenter, double-blind randomized trial. Diabetes Metab J. 2024;48(5):915-28. DOI:10.4093/dmj.2023.0259
102. Kim JM, Kim SS, Kim JH, et al. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: A randomized, open-label, multicenter, parallel-controlled study. Diabetes Metab J. 2020;44(1):67-77. DOI:10.4093/dmj.2018.0274
103. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615-22. DOI:10.1210/jc.2011-2243
104. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088-96. DOI:10.1111/j.1463-1326.2011.01463.x
105. Поздняк А.О., Елсукова О.С., Никитина Е.А. Влияние фиксированной комбинации алоглиптина и пиоглитазона на факторы риска возникновения сердечно-сосудистых заболеваний у пациентов с сахарным диабетом 2 типа. Практическая медицина. 2024;22(3):63-7 [Pozdnyak AO, Elsukova OS, Nikitina EA. Effect of a fixed combination of alogliptin and pioglitazone on risk factors for cardiovascular diseases in patients with type 2 diabetes mellitus. Practical Medicine. 2024;22(3):63-7 (in Russian)]. DOI:10.32000/2072-1757-2024-3-63-67
106. Pan C, Han P, Ji Q, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9(4):386-95. DOI:10.1111/1753-0407.12425
107. Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-8. DOI:10.2337/dc10-0159
108. Aoki K, Nagakura M, Taguri M, et al. Effect of switching from an anti-diabetic loose dose combination to a fixed dose combination regimen at equivalent dosage for 6 months on glycemic control in Japanese Patients with type 2 diabetes: A pilot study. J Clin Med Res. 2017;9(8):719-24. DOI:10.14740/jocmr3067w
109. Aoki C, Suzuki K, Kuroda H, et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017;79(1):9-16. DOI:10.18999/nagjms.79.1.9
110. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915-25. DOI:10.1007/s00125-011-2447-3
111. Okamura K, Shirai K, Miyazaki M, et al. Investigation of a dipeptidyl peptidase-4 inhibitor/thiazolidinedione combination drug for patients with type 2 diabetes and poor glycemic control: Difficulty with patient enrollment. J Clin Med Res. 2019;11(2):89-97. DOI:10.14740/jocmr3558

________________________________________________

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org. Accessed: 05.06.2025.
2. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: Dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104-23 (in Russian). DOI:10.14341/DM13035
3. Registr sakharnogo diabeta. Available at: https://sd.diaregistry.ru/content/o-proekte.html#content. Accessed: 05.06.2025 (in Russian).
4. Misra S, Holman N, Barron E, et al. Characteristics and care of young people with type 2 diabetes included in the national diabetes audit datasets for England. Diabet Med. 2023;40(1):e14940. DOI:10.1111/dme.14940
5. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovascular Therapy and Prevention. 2024;23(3):3996 (in Russian). DOI:10.15829/1728-8800-2024-3996
6. Antsiferov MB, Kotenko ON, Kobalava ZD, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes admitted to multidisciplinary hospitals: results of a prospective observational multicenter study (CREDO). Diabetes mellitus. 2024;27(3):204-13 (in Russian). DOI:10.14341/DM13146
7. Antsiferov MB, Kobalava ZhD, Demidova TY, et al. Prevalence of heart failure among hospitalized patient with T2D: results of a prospective observational multicenter study (CREDO). Diabetes Mellitus. 2024;27(1):4-14 (in Russian).  DOI:10.14341/DM13124
8. Rymar OD, Shcherbakova LV, Shchetinina AO, et al. Type 2 diabetes: basic clinical and laboratory parameters and risk of cardiovascular death. Russian Journal of Cardiology. 2020;25(4):3822 (in Russian). DOI:10.15829/1560-4071-2020-3822
9. Bin Rakhis SA Sr, AlDuwayhis NM, Aleid N, et al. Glycemic control for type 2 diabetes mellitus patients: A systematic review. Cureus. 2022;14(6):e26180. DOI:10.7759/cureus.26180
10. Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 Million person-years of observation. Lancet Diabetes Endocrinol. 2023;11(10):731-42. DOI:10.1016/S2213-8587(23)00223-1
11. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of Specialized Diabetes Care. Ed. by II Dedov, MV Shestakova, AYu Mayorov. 11th Edition. Diabetes Mellitus. 2023;26(2S):1-231 (in Russian). DOI:10.14341/DM13042 
12. Motkova SI, Savelyeva LV, Rudina LM, et al. Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application “Life is easy” programme in Russia. Diabetes Mellitus. 2019;22(2):115-26 (in Russian). DOI:10.14341/DM1000
13. Misnikova IV, Kovaleva YuA, Isakov MА, Dreval AV. The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow Region Register. Diabetes Mellitus. 2019;22(3):206-16 (in Russian). DOI:10.14341/DM10084
14. Druk IV, Snarskaya DI, Goroshchenya OI. Potential overtreatment of type 2 diabetes therapy in real clinical practice: Omsk Oblast Register data. Diabetes mellitus. 2021;24(2):100-10 (in Russian). DOI:10.14341/DM12469
15. Kurkin DV, Makarova EV, Krysanov IS, et al. Characteristics of purchases of hypoglycemic agents in pharmacy retail sector in 2016–2020 years dynamics. Problems of Endocrinology. 2023;69(4):50-60 (in Russian). DOI:10.14341/probl13200
16. Khunti K, Zaccardi F, Amod A, et al. Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia. 2025;68(1):17-28. DOI:10.1007/s00125-024-06254-w 
17. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl. 1):S158-78. DOI:10.2337/dc24-S009. Erratum in: Diabetes Care. 2024;47(7):1238. DOI:10.2337/dc24-er07a 
18. ElSayed NA, Aleppo G, Aroda VR, et al.; on behalf of the American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S140-57. DOI:10.2337/dc23-S009 
19. Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: Early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11(11):2465-76. DOI:10.1007/s13300-020-00926-7
20. Shestakova MV, Antsiferov MB, Ametov AS, et al. What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019. Diabetes mellitus. 2020;23(1):106-10 (in Russian). DOI:10.14341/DM12404
21. Kalra S, Das AK, Priya G, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7. DOI:10.4103/jfmpc.jfmpc_843_20 
22. Verbovoy AF, Verbovaya NI, Dolgikh YuA. Fixed combinations of hypoglycemic drugs in the treatment of patients with type 2 diabetes. Meditsinskiy Sovet = Medical Council. 2022;16(23):199-204 (in Russian). DOI:10.21518/2079-701X-2022-16-23-199-204
23. Ndefo UA, Okoli O, Erowele G. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm. 2014;71(2):103-9. DOI:10.2146/ajhp130131 
24. Zyrianov SK, Butranova OI. Sakharosnizhaiushchie sredstva v geriatrii. Moscow: GEOTAR-Media, 2024 (in Russian).
25. Dudkowski C, Tsai M, Liu J, et al. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2017;73(3):279-88. DOI:10.1007/s00228-016-2175-1
26. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499-512. DOI:10.1016/j.clinthera.2008.03.004
27. Okondo MC, Johnson DC, Sridharan R, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017;13:46-53. DOI:10.1038/nchembio.2229
28. Jones L, Jones AM. Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain? Pharmacol Res Perspect. 2022;10(6):e01029. DOI:10.1002/prp2.1029
29. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501-14. DOI:10.1007/BF03261927
30. Kaku K, Kisanuki K, Shibata M, Oohira T. Benefit-Risk assessment of alogliptin for the treatment of type 2 diabetes mellitus. Drug Saf. 2019;42(11):1311-27. DOI:10.1007/s40264-019-00857-8
31. Lobanova KG, Severina AS, Martinov SA, et al. Glycemic control in patients with diabetes mellitus on hemodialysis. Terapevticheskii Arkhiv (Ter. Arkh). 2019;91(10):124-34 (in Russian). DOI:10.26442/00403660.2019.10.000352
32. Park SH, Nam JY, Han E, et al. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis. Medicine (Baltimore). 2016;95(32):e4543. DOI:10.1097/MD.0000000000004543 
33. Nakamura Y, Hasegawa H, Tsuji M, et al. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes. 2015;6(6):840-9. DOI:10.4239/wjd.v6.i6.840
34. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: A meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord. 2013;13:9. DOI:10.1186/1472-6823-13-9
35. Marino AB, Cole SW. Alogliptin: Safety, efficacy, and clinical implications. J Pharm Pract. 2015;28(1):99-106. DOI:10.1177/0897190014522063
36. Shestakova MV, Kachko VA. ENTIRE: real clinical practice study on alogliptin application in the treatment of patients with type 2 diabetes mellitus in the Russian Federation. Russian Medical Journal. 2019;27(8-1):3-10 (in Russian).
37. Fadeev VV. Results of the first retrospective study of alogliptin compared with other oral hypoglycemic drugs in patients with type 2 diabetes mellitus in Russia ARRIVAL. Effektivnaya Pharmacoterapiya. 2023;19(12):6-14 (in Russian). DOI:10.33978/2307-3586-2023-19-12-6-14
38. Cavender MA, White WB, Liu Y, et al. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clin Cardiol. 2018;41(8):1022-7. DOI:10.1002/clc.22960
39. Mancheva M, Paljoskovska Jordanova S, Bosevski M. Carotid intima media thickness is in a relation to risk factors for coronary artery disease. Angiol Sosud Khir. 2020;26(4):11-6. DOI:10.33529/ANGIO2020412
40. Lv Q, Yang Y, Lv Y, et al. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: A systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2024;15:1403606. DOI:10.3389/fendo.2024.1403606
41. Mita T, Katakami N, Yoshii H, et al. Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: An extension of the SPEAD-A study. Sci Rep. 2023;13(1):14649. DOI:10.1038/s41598-023-41036-1
42. Layman SN, Elliott WV, Neu DW, et al. Alogliptin and heart failure outcomes in patients with type 2 diabetes. J Pharm Pract. 2024;37(2):410-4. DOI:10.1177/08971900221135656
43. Enzan N, Matsushima S, Kaku H, et al. Beneficial effects of dipeptidyl peptidase-4 inhibitors on heart failure with preserved ejection fraction and diabetes. JACC Asia. 2023;3(1):93-104. DOI:10.1016/j.jacasi.2022.09.015
44. Echouffo-Tcheugui JB, Kaze AD, Fonarow GC, Dagogo-Jack S. Severe hypoglycemia and incident heart failure among adults with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(3):e955-62. DOI:10.1210/clinem/dgab794
45. Shibuki K, Shimada S, Aoyama T. Meta-analysis of 11 heterogeneous studies regarding dipeptidyl peptidase 4 inhibitor add-on therapy for type 2 diabetes mellitus patients treated with insulin. J Diabetes Res. 2020;2020:6321826. DOI:10.1155/2020/6321826
46. Shestakova MV, Shestakova EA, Kachko VA. Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: Additional results of the ENTIRE study. Problems of Endocrinology. 2020;66(2):49-60 (in Russian). DOI:10.14341/probl12273
47. Kutoh E, Kuto AN, Akiyama M, et al. Alogliptin: A DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. Eur J Clin Pharmacol. 2023;79(7):947-59. DOI:10.1007/s00228-023-03506-3
48. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: A 2-year study. Diabetes Obes Metab. 2014;16(12):1239-46. DOI:10.1111/dom.12377
49. El-Sahar AE, Shiha NA, El Sayed NS, Ahmed LA. Alogliptin attenuates lipopolysaccharide-induced neuroinflammation in mice through modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 signaling pathways. Int J Neuropsychopharmacol. 2021;24(2):158-69. DOI:10.1093/ijnp/pyaa078
50. El-Sayed SS, Ali SO, Ibrahim WW. Potential neuroprotective and autophagy-enhancing effects of alogliptin on lithium/pilocarpine-induced seizures in rats: Targeting the AMPK/SIRT1/Nrf2 axis. Life Sci. 2024;352:122917. DOI:10.1016/j.lfs.2024.122917
51. Safar MM, Abdelkader NF, Ramadan E, et al. Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease. Life Sci. 2021;287:120132. DOI:10.1016/j.lfs.2021.120132 
52. Dhureja M, Deshmukh R. Impact of alogliptin on lipopolysaccharide-induced experimental Parkinson's disease: Unrevealing neurochemical and histopathological alterations in rodents. Eur J Pharmacol. 2024;975:176635. DOI:10.1016/j.ejphar.2024.176635
53. McFarthing K, Buff S, Rafaloff G, et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2024 Update. J Parkinsons Dis. 2024;14(5):899-912. DOI:10.3233/JPD-240272
54. Ueki K, Tanizawa Y, Nakamura J, et al. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: A 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Res Care. 2021;9(1):e001787. DOI:10.1136/bmjdrc-2020-001787
55. Pradhan R, Yu OHY, Platt RW, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: A UK population-based cohort study. BMJ Open Diabetes Res Care. 2023;11(6):e003550. DOI:10.1136/bmjdrc-2023-003550
56. Zhang YS, Zheng YD, Yuan Y, et al. Effects of anti-diabetic drugs on fracture risk: A systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2021;12:735824. DOI:10.3389/fendo.2021.735824
57. Petunina NA, Goncharova EV, Kuzina IA, et al. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes Mellitus. 2022;25(5):504-13 (in Russian). DOI:10.14341/DM12859
58. Christensen ML, Meibohm B, Capparelli EV, et al. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol. 2005;45(10):1137-44. DOI:10.1177/0091270005279578
59. Alam F, Islam MA, Mohamed M, et al. Efficacy and safety of pioglitazone monotherapy in type 2 diabetes mellitus: A systematic review and meta-analysis of randomised controlled trials. Sci Rep. 2019;9(1):5389. DOI:10.1038/s41598-019-41854-2
60. Ipsen EØ, Madsen KS, Chi Y, et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;11(11):CD013516. DOI:10.1002/14651858.CD013516.pub2
61. White U, Fitch MD, Beyl RA, et al. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: A randomised controlled trial. Diabetologia. 2021;64(1):159-67. DOI:10.1007/s00125-020-05281-7
62. Arbas R, Dayrit SA, Dimalanta A, et al. A meta-analysis of randomized clinical trials on the effect of metformin vs. pioglitazone monotherapy on plasma adiponectin levels among patients with diabetes mellitus. Egypt J Intern Med. 2024;36:5. DOI:10.1186/s43162-023-00269-2
63. Chang ML, Tai J, Cheng JS, et al. Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study. Diabetes Obes Metab. 2024;26(7):2969-78. DOI:10.1111/dom.15622
64. Choi SS, Park J, Choi JH. Revisiting PPARγ as a target for the treatment of metabolic disorders. BMB Rep. 2014;47(11):599-608. DOI:10.5483/bmbrep.2014.47.11.174 
65. Ostroumova OD, Goloborodova IV. Drug-induced heart failure (Part 1: The urgency of the problem, the prevalence, the effect of certain groups of drugs on the risk of development/progression heart failure). Safety and Risk of Pharmacotherapy. 2020;8(1):23-35 (in Russian). DOI:10.30895/2312-7821-2020-8-1-23-35
66. Cheng D, Gao H, Li W. Long-term risk of rosiglitazone on cardiovascular events – A systematic review and meta-analysis. Endokrynol Pol. 2018;69(4):381-94. DOI:10.5603/EP.a2018.0036
67. Salukhov VV, Kovalevskaya EA. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy sovet = Medical Council. 2022;(10):10-21 (in Russian). DOI:10.21518/2079-701X-2022-16-10-10-21 
 68. Ametov АS, Pyanykh OP, Vovk PS. Benefits for pioglitazone in prevention and treatment of type 2 diabetes mellitus and its complications. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Training. 2022;11(2):56-63 (in Russian). DOI:10.33029/2304-9529-2022-11-2-56-63
69. Nesti L, Tricò D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: A new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. DOI:10.1186/s12933-021-01294-7
70. Yen FS, Wang HC, Pan CW, et al. Pioglitazone exposure reduced the risk of all-cause mortality in insulin-treated patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2020;105(3):dgz026. DOI:10.1210/clinem/dgz026
71. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927. DOI:10.1136/bmjopen-2016-013927 
72. Lebovitz HE. Thiazolidinediones: The forgotten diabetes medications. Curr Diab Rep. 2019;19(12):151. DOI:10.1007/s11892-019-1270-y 
73. Lu Y, Ma D, Xu W, et al. Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J Diabetes Investig. 2015;6(1):78-86. DOI:10.1111/jdi.12246
74. Lee M, Saver JL, Liao HW, et al. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke. 2017;48(2):388-93. DOI:10.1161/STROKEAHA.116.013977
75. de Jong M, van der Worp HB, van der Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16(1):134. DOI:10.1186/s12933-017-0617-4
76. Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: A meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252. DOI:10.1210/clinem/dgz252
77. Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: A meta-analysis of its risks and benefits from prospective trials. Sci Rep. 2020;10(1):15781. DOI:10.1038/s41598-020-72967-8
78. Mannucci E, Giaccari A, Gallo M, et al.; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2022;32(3):529-36. DOI:10.1016/j.numecd.2021.12.006
79. Yang J, Shi X, Wang Y, et al. Multi-target neuroprotection of thiazolidinediones on Alzheimer's disease via neuroinflammation and ferroptosis. J Alzheimers Dis. 2023;96(3):927-45. DOI:10.3233/JAD-230593
80. Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. Ann Neurol. 2015;78(2):284-94. DOI:10.1002/ana.24439
81. Lu CH, Yang CY, Li CY, et al. Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: A population-based longitudinal study. Diabetologia. 2018;61(3):562-73. DOI:10.1007/s00125-017-4499-5
82. Megiri N, Mostafa YM, Ahmed A, et al. Pioglitazone ameliorates hippocampal neurodegeneration, disturbances in glucose metabolism and AKT/mTOR signaling pathways in pentyelenetetrazole-kindled mice. Pharmaceuticals (Basel). 2022;15(9):1113. DOI:10.3390/ph15091113
83. Lee HM, Hahn SJ, Choi BH. The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state. Korean J Physiol Pharmacol. 2022;26(2):135-44. DOI:10.4196/kjpp.2022.26.2.135 
84. Lee HM, Yoon SH, Kim MG, et al. Effects of rosiglitazone, an antidiabetic drug, on Kv3.1 channels. Korean J Physiol Pharmacol. 2023;27(1):95-103. DOI:10.4196/kjpp.2023.27.1.95
85. Harrer DC, Lüke F, Pukrop T, et al. Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. Front Oncol. 2024;13:1289222. DOI:10.3389/fonc.2023.1289222
86. Davidson MB, Pan D. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. Diabetes Res Clin Pract. 2018;135:102-10. DOI:10.1016/j.diabres.2017.11.002
87. Espinoza SE, Wang CP, Tripathy D, et al. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. Age (Dordr). 2016;38(5-6):485-93. DOI:10.1007/s11357-016-9946-6
88. Yen CL, Wu CY, Tsai CY, et al. Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: A national cohort study. Aging (Albany NY). 2023;15(7):2721-33. DOI:10.18632/aging.204643
89. Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A meta-analysis. Front Endocrinol (Lausanne). 2021;12:615409. DOI:10.3389/fendo.2021.615409. Corrigendum: Front Endocrinol (Lausanne). 2021;13:840299. DOI:10.3389/fendo.2022.840299
90. Karim A, Laurent A, Munsaka M, et al. Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol. 2009;49(10):1210-9. DOI:10.1177/0091270009338938
91. Scheen AJ. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(6):1005-20. DOI:10.1517/17425255.2015.1041499
92. Hwang I, Kim Y, Yoo H, et al. Pharmacokinetic/pharmacodynamic interaction between evogliptin and pioglitazone in healthy male subjects. Drug Des Devel Ther. 2020;14:4493-502. DOI:10.2147/DDDT.S275336
93. Anson M, Henney AE, Zhao SS, et al. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database. Diabetes Obes Metab. 2024;26(7):2606-23. DOI:10.1111/dom.15576
94. Tomlinson B, Chan P, Lam CWK. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2022;23(1):29-42. DOI:10.1080/14656566.2021.1985465
95. Demidova ТYu, Ushanova FО, Zharkova PО. Glycemic and non-glycemic benefits of using the fixed dose combination of alogliptin and pioglitazone in management of diabetes mellitus. FOCUS Endocrinology. 2021;4:39-48 (in Russian). DOI:10.47407/ef2021.2.4.0048
96. Pratley RE, Reusch JE, Fleck PR, et al.; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361-71. DOI:10.1185/03007990903156111
97. Kaku K, Itayasu T, Hiroi S, et al. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028-35. DOI:10.1111/j.1463-1326.2011.01460.x
98. Kaku K, Katou M, Igeta M, et al. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab. 2015;17(12):1198-201. DOI:10.1111/dom.12555
99. Kim HJ, Jeong IK, Hur KY, et al. Comparison of efficacy of glimepiride, alogliptin, and alogliptin-pioglitazone as the initial periods of therapy in patients with poorly controlled type 2 diabetes mellitus: An open-label, multicenter, randomized, controlled study. Diabetes Metab J. 2022;46(5):689-700. DOI:10.4093/dmj.2021.0183
100. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565-74. DOI:10.1530/EJE-13-0639
101. Park JY, Lee J, Choi YH, et al. Efficacy and safety of alogliptin-pioglitazone combination for type 2 diabetes mellitus poorly controlled with metformin: A multicenter, double-blind randomized trial. Diabetes Metab J. 2024;48(5):915-28. DOI:10.4093/dmj.2023.0259
102. Kim JM, Kim SS, Kim JH, et al. Efficacy and safety of pioglitazone versus glimepiride after metformin and alogliptin combination therapy: A randomized, open-label, multicenter, parallel-controlled study. Diabetes Metab J. 2020;44(1):67-77. DOI:10.4093/dmj.2018.0274
103. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615-22. DOI:10.1210/jc.2011-2243
104. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088-96. DOI:10.1111/j.1463-1326.2011.01463.x
105. Pozdnyak AO, Elsukova OS, Nikitina EA. Effect of a fixed combination of alogliptin and pioglitazone on risk factors for cardiovascular diseases in patients with type 2 diabetes mellitus. Practical Medicine. 2024;22(3):63-7 (in Russian). DOI:10.32000/2072-1757-2024-3-63-67
106. Pan C, Han P, Ji Q, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9(4):386-95. DOI:10.1111/1753-0407.12425
107. Rosenstock J, Inzucchi SE, Seufert J, et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-8. DOI:10.2337/dc10-0159
108. Aoki K, Nagakura M, Taguri M, et al. Effect of switching from an anti-diabetic loose dose combination to a fixed dose combination regimen at equivalent dosage for 6 months on glycemic control in Japanese Patients with type 2 diabetes: A pilot study. J Clin Med Res. 2017;9(8):719-24. DOI:10.14740/jocmr3067w
109. Aoki C, Suzuki K, Kuroda H, et al. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Nagoya J Med Sci. 2017;79(1):9-16. DOI:10.18999/nagjms.79.1.9
110. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915-25. DOI:10.1007/s00125-011-2447-3
111. Okamura K, Shirai K, Miyazaki M, et al. Investigation of a dipeptidyl peptidase-4 inhibitor/thiazolidinedione combination drug for patients with type 2 diabetes and poor glycemic control: Difficulty with patient enrollment. J Clin Med Res. 2019;11(2):89-97. DOI:10.14740/jocmr3558

О.И. Бутранова*¹, С.К. Зырянов^1,2, А.Р. Мельникова¹, А.Е. Мацепуро<sup>1

1</sup>ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы», Москва, Россия;
²ГБУЗ г. Москвы «Городская клиническая больница №24» Департамента здравоохранения г. Москвы, Москва, Россия
*butranova-oi@rudn.ru

________________________________________________

Olga I. Butranova*¹, Sergey K. Zyryanov^1,2, Anna R. Melnikova¹, Anastasia E. Matsepuro<sup>1

1</sup>Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow, Russia; 
²City Clinical Hospital No. 24, Moscow, Russia
*butranova-oi@rudn.ru